Hjem › Galdevejscancer › Californien
Galdevejscancer kliniske forsøg i Californien
20 studier for Galdevejscancer søger deltagere på steder i Californien.
Byer i Californien
Officiel studietekst (engelsk)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- City of Hope - Duarte Cancer Center, Duarte
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. okt. 2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Orange
- Research Site, Palo Alto
- Research Site, Santa Rosa
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- City of Hope (Site 107), Duarte
- University of California at Irvine (Site 101), Orange
- UCLA Medical Center (Site 117), Santa Monica
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Orange
- og 1 flere
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- UCLA ( Site 0317), Los Angeles
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Los Angeles
- Research Site, Santa Rosa
RekruttererFase 2
Alder 18 til 130 · Alle køn · Opdateret 23. sep. 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- City of Hope, Duarte
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
- og 1 flere
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Los Angeles
- Avenzo Therapeutics Recruiting Site, Los Angeles
RekruttererFase 1/2
Alder 18 til 75 · Alle køn · Opdateret 4. sep. 2026 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Hoag Family Cancer Institute, Newport Beach
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Fullerton
- Research Site, La Jolla
- Research Site, Los Angeles
- og 3 flere
RekruttererFase 3
Alder 18 til 99 · Alle køn · Opdateret 19. aug. 2026 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 5. aug. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Precision NextGen Oncology & Research Center, Beverly Hills
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
- University of California Los Angeles Rheumatology, Westwood, Los Angeles
RekruttererFase 2
Alder 8 og opefter · Alle køn · Opdateret 27. jul. 2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
- University of California, Davis Comprehensive Cancer Center, Sacramento
Rekrutterer
Alder 18 og opefter · Alle køn · Opdateret 2. jul. 2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Cedars-Sinai Medical Center, Los Angeles
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The City of Hope National Medical Center, Duarte
- Hoag Memorial Hospital, Newport Beach
RekruttererFase 1
Alder 16 og opefter · Alle køn · Opdateret 2. jun. 2026 · NCT07197554Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Beverly Hills Cancer Center, Beverly Hills
- UC San Diego Moores Cancer Center, La Jolla
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. apr. 2026 · NCT05733598Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Stern Center for Cancer Clinical Trials and Research, Orange
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 5. mar. 2026 · NCT04900818Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- Cedars-Sinai Medical Center, Los Angeles
Rekrutterer
Alder 18 til 99 · Alle køn · Opdateret 20. feb. 2026 · NCT04907643A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 11. dec. 2025 · NCT06943521Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.